OBJECTIVE: The purpose of this study was to review the scientific evidence for neurobiological rationale, efficacy, tolerability and cost effectiveness of antipsychotic polypharmacy (APP). DATA SOURCES: A systematic literature search of Medline, Embase, Ovid and the Cochrane Database of Systematic Reviews until April 2012 was carried out. RESULTS: Theories behind APP have only modest pre-clinical and clinical evidence. We found limited statistical evidence supporting modest efficacy of APP in patients with psychotic symptoms refractory to clozapine. APP is associated with increased mortality, metabolic syndrome, decreased cognitive functioning, high dose prescription and non-adherence. It brings up extra costs, lacking evidence for cost-effectiveness. CONCLUSIONS: Pre-clinical studies underpinning neurobiological hypotheses in APP are lacking. Evidence supporting efficacy of APP is limited with modest beneficial clinical relevance. APP is associated with several serious adverse effects and increased health costs. In the absence of more convincing pre-clinical support and clinical evidence we advise adherence to existing guidelines and limiting combinations of antipsychotics (in consideration with other pharmacotherapeutic, somatic and psychotherapeutic options) to patients with clozapine-refractory psychosis in well-evaluated individual trials that might need 10 weeks or more.
OBJECTIVE: The purpose of this study was to review the scientific evidence for neurobiological rationale, efficacy, tolerability and cost effectiveness of antipsychotic polypharmacy (APP). DATA SOURCES: A systematic literature search of Medline, Embase, Ovid and the Cochrane Database of Systematic Reviews until April 2012 was carried out. RESULTS: Theories behind APP have only modest pre-clinical and clinical evidence. We found limited statistical evidence supporting modest efficacy of APP in patients with psychotic symptoms refractory to clozapine. APP is associated with increased mortality, metabolic syndrome, decreased cognitive functioning, high dose prescription and non-adherence. It brings up extra costs, lacking evidence for cost-effectiveness. CONCLUSIONS: Pre-clinical studies underpinning neurobiological hypotheses in APP are lacking. Evidence supporting efficacy of APP is limited with modest beneficial clinical relevance. APP is associated with several serious adverse effects and increased health costs. In the absence of more convincing pre-clinical support and clinical evidence we advise adherence to existing guidelines and limiting combinations of antipsychotics (in consideration with other pharmacotherapeutic, somatic and psychotherapeutic options) to patients with clozapine-refractory psychosis in well-evaluated individual trials that might need 10 weeks or more.
Authors: Gary Remington; Ofer Agid; George Foussias; Gagan Fervaha; Hiroyoshi Takeuchi; Jimmy Lee; Margaret Hahn Journal: Can J Psychiatry Date: 2015-03 Impact factor: 4.356
Authors: Shannon N Saldaña; Brooks R Keeshin; Anna M Wehry; Thomas J Blom; Michael T Sorter; Melissa P DelBello; Jeffrey R Strawn Journal: Pharmacotherapy Date: 2014-07-03 Impact factor: 4.705
Authors: Alexis E Horace; Negar Golchin; Elia M Pestana Knight; Neal V Dawson; Xuan Ma; James A Feinstein; Hannah K Johnson; Lawrence Kleinman; Paul M Bakaki Journal: Paediatr Drugs Date: 2020-02 Impact factor: 3.022
Authors: Negar Golchin; Hannah Johnson; Paul M Bakaki; Neal Dawson; Elia M Pestana Knight; Sharon B Meropol; Rujia Liu; James A Feinstein; Shari D Bolen; Lawrence C Kleinman; Alexis Horace Journal: Drugs Ther Perspect Date: 2019-07-12
Authors: Denise Razzouk; Monica Kayo; Aglaé Sousa; Guilherme Gregorio; Hugo Cogo-Moreira; Andrea Alves Cardoso; Jair de Jesus Mari Journal: PLoS One Date: 2015-04-08 Impact factor: 3.240
Authors: Tomasz Pawełczyk; Marta Grancow; Magdalena Kotlicka-Antczak; Elżbieta Trafalska; Piotr Gębski; Janusz Szemraj; Natalia Żurner; Agnieszka Pawełczyk Journal: BMC Psychiatry Date: 2015-05-02 Impact factor: 3.630